Brind.

FDA approved Ogsiveo and Mirdametinib, while EMA recommended approval for Ogsiveo, for Merck KGaA.

1 report, 0 independent Updated Jul 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

FDA approved Ogsiveo and Mirdametinib, while EMA recommended approval for Ogsiveo, for Merck KGaA.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Unknown outlet